Takara Bio Completes Absorption of Subsidiary ViSpot

MT Newswires Live

2025/05/02

Takara Bio (TYO:4974) completed the absorption-type merger of its wholly owned subsidiary ViSpot Inc. on May 1, as scheduled, according to a same-day filing on the Tokyo Stock Exchange.

The simplified merger, first disclosed on March 27, is intended to streamline management and support business expansion.

ViSpot, based in Kobe, provided viral safety testing services. Takara Bio manufactures reagents and instruments and operates a gene therapy CDMO business.

Price (JPY): $822.00, Change: $+1.0, Percent Change: +0.12%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2532855128"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532855128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532855128?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 09:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532855128","market":"nz","top_or_hot":-1,"title":"Takara Bio Completes Absorption of Subsidiary ViSpot","media":"MT Newswires Live","content":"<html><body><p> Takara Bio (TYO:4974) completed the absorption-type merger of its wholly owned subsidiary ViSpot Inc. on May 1, as scheduled, according to a same-day filing on the Tokyo Stock Exchange.</p><p>The simplified merger, first disclosed on March 27, is intended to streamline management and support business expansion.</p><p>ViSpot, based in Kobe, provided viral safety testing services. Takara Bio manufactures reagents and instruments and operates a gene therapy CDMO business.</p><p>Price (JPY): $822.00, Change: $+1.0, Percent Change: +0.12%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takara Bio Completes Absorption of Subsidiary ViSpot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakara Bio Completes Absorption of Subsidiary ViSpot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-02 09:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takara Bio (TYO:4974) completed the absorption-type merger of its wholly owned subsidiary ViSpot Inc. on May 1, as scheduled, according to a same-day filing on the Tokyo Stock Exchange.</p><p>The simplified merger, first disclosed on March 27, is intended to streamline management and support business expansion.</p><p>ViSpot, based in Kobe, provided viral safety testing services. Takara Bio manufactures reagents and instruments and operates a gene therapy CDMO business.</p><p>Price (JPY): $822.00, Change: $+1.0, Percent Change: +0.12%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JPY","symbol_name":"Lazard Japanese Equity ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532855128","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532855128","pubTimestamp":1746148822,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takara Bio  completed the absorption-type merger of its wholly owned subsidiary ViSpot Inc. on May 1, as scheduled, according to a same-day filing on the Tokyo Stock Exchange.The simplified merger, first disclosed on March 27, is intended to streamline management and support business expansion.ViSpot, based in Kobe, provided viral safety testing services. Takara Bio manufactures reagents and instruments and operates a gene therapy CDMO business.Price : $822.00, Change: $+1.0, Percent Change: +0.12%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JPY":"Lazard Japanese Equity ETF"},"translate_title":"宝生物完成对子公司ViSpot的吸收","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JPY":1},"content_text":"Takara Bio (TYO:4974) completed the absorption-type merger of its wholly owned subsidiary ViSpot Inc. on May 1, as scheduled, according to a same-day filing on the Tokyo Stock Exchange.The simplified merger, first disclosed on March 27, is intended to streamline management and support business expansion.ViSpot, based in Kobe, provided viral safety testing services. Takara Bio manufactures reagents and instruments and operates a gene therapy CDMO business.Price (JPY): $822.00, Change: $+1.0, Percent Change: +0.12%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}